NPI: 1477938686 · FLINT, MI 48507 · Clinical Medical Laboratory · NPI assigned 07/29/2015
Authorized official LOY, STEVEN controls 20+ related entities in our dataset. Read more
| Authorized Official | LOY, STEVEN (VP - CFO) |
| NPI Enumeration Date | 07/29/2015 |
Other providers sharing the same authorized official: LOY, STEVEN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 874 | $12K |
| 2019 | 22,389 | $114K |
| 2020 | 30,607 | $273K |
| 2021 | 47,636 | $412K |
| 2022 | 41,881 | $393K |
| 2023 | 35,970 | $320K |
| 2024 | 31,350 | $228K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 15,249 | 10,285 | $241K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 7,062 | 6,979 | $102K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 7,301 | 7,282 | $97K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 6,386 | 6,310 | $95K |
| 84443 | Thyroid stimulating hormone (TSH) | 9,828 | 9,782 | $84K |
| 83013 | 1,899 | 1,894 | $80K | |
| 80053 | Comprehensive metabolic panel | 14,164 | 13,411 | $77K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 16,028 | 14,328 | $66K |
| 80061 | Lipid panel | 10,938 | 10,901 | $66K |
| 83036 | Hemoglobin; glycosylated (A1C) | 9,228 | 9,186 | $47K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2,798 | 2,794 | $45K |
| 80074 | 1,864 | 1,841 | $41K | |
| 84439 | 7,080 | 7,064 | $35K | |
| 82607 | 4,295 | 4,286 | $35K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2,634 | 2,631 | $35K |
| 87390 | 3,143 | 3,130 | $34K | |
| 88307 | 268 | 260 | $32K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 8,972 | 8,729 | $30K |
| 87070 | 5,897 | 5,835 | $23K | |
| 88312 | 1,167 | 882 | $21K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 370 | 319 | $20K |
| 86702 | 3,182 | 3,169 | $20K | |
| 86696 | 1,762 | 1,654 | $18K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1,484 | 1,468 | $16K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 562 | 450 | $15K |
| 86701 | 3,169 | 3,157 | $15K | |
| 87480 | 2,006 | 1,981 | $15K | |
| 87077 | 3,151 | 3,099 | $14K | |
| 87660 | 1,940 | 1,916 | $14K | |
| 87510 | 1,941 | 1,916 | $14K | |
| 86803 | 1,968 | 1,965 | $13K | |
| 87186 | 3,288 | 3,234 | $13K | |
| 86235 | 399 | 399 | $13K | |
| 86695 | 1,710 | 1,601 | $13K | |
| 88304 | 1,518 | 1,218 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2,546 | 2,066 | $12K |
| 84154 | 1,119 | 1,117 | $12K | |
| 84481 | 1,923 | 1,922 | $12K | |
| 86003 | 206 | 201 | $11K | |
| 86038 | 1,628 | 1,622 | $10K | |
| 83655 | 1,225 | 1,224 | $8K | |
| 86200 | 863 | 863 | $7K | |
| 86694 | 913 | 911 | $7K | |
| 82105 | 671 | 670 | $7K | |
| 82746 | 881 | 878 | $6K | |
| 86480 | 223 | 223 | $6K | |
| 82043 | 1,665 | 1,663 | $6K | |
| 86376 | 665 | 662 | $6K | |
| 82570 | 1,713 | 1,707 | $6K | |
| 84144 | 385 | 385 | $5K | |
| 83014 | 900 | 900 | $5K | |
| 84153 | 539 | 538 | $5K | |
| 82728 | 672 | 666 | $4K | |
| 84702 | 584 | 555 | $4K | |
| 84165 | 422 | 407 | $4K | |
| 84403 | 237 | 237 | $3K | |
| 86780 | 555 | 555 | $3K | |
| 82248 | 1,854 | 1,854 | $3K | |
| 86592 | 1,627 | 1,617 | $3K | |
| 86706 | 723 | 721 | $3K | |
| 83735 | 950 | 755 | $3K | |
| 84146 | 267 | 266 | $3K | |
| 85027 | 800 | 780 | $3K | |
| 87340 | 698 | 696 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 161 | 140 | $3K |
| 83540 | 856 | 848 | $3K | |
| 83721 | 378 | 378 | $2K | |
| 86334 | 227 | 219 | $2K | |
| 86140 | 1,264 | 819 | $2K | |
| 82627 | 155 | 155 | $2K | |
| 83550 | 513 | 511 | $2K | |
| 84425 | 200 | 199 | $2K | |
| 87147 | 837 | 832 | $2K | |
| 80164 | 304 | 296 | $2K | |
| 86300 | 190 | 189 | $2K | |
| 83718 | 343 | 343 | $2K | |
| 84450 | 589 | 589 | $2K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 37 | 37 | $2K |
| 87205 | 862 | 851 | $2K | |
| 83525 | 296 | 295 | $2K | |
| 82626 | 163 | 163 | $2K | |
| 82085 | 365 | 364 | $2K | |
| 86225 | 179 | 179 | $2K | |
| 84460 | 606 | 606 | $1K | |
| 81003 | 1,032 | 1,020 | $1K | |
| 81001 | 900 | 859 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 125 | 125 | $1K |
| 87634 | 31 | 31 | $1K | |
| 83001 | 84 | 84 | $1K | |
| 88342 | 53 | 38 | $1K | |
| 82785 | 105 | 104 | $1K | |
| 87522 | Neg quan hep c or qual rna | 53 | 53 | $1K |
| 36415 | Collection of venous blood by venipuncture | 2,294 | 1,972 | $967.50 |
| 86258 | 57 | 57 | $913.84 | |
| 88142 | 103 | 103 | $910.11 | |
| 86364 | 57 | 57 | $884.22 | |
| 83002 | 69 | 69 | $878.38 | |
| 85652 | 1,034 | 721 | $856.00 | |
| 83690 | 227 | 225 | $845.59 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 18 | 17 | $831.81 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 48 | 43 | $826.50 |
| 82550 | 216 | 187 | $790.69 | |
| 86800 | 76 | 76 | $745.08 | |
| 83970 | 45 | 45 | $744.52 | |
| 84402 | 42 | 42 | $739.50 | |
| 82150 | 170 | 167 | $696.85 | |
| 84479 | 203 | 202 | $649.56 | |
| 82784 | 32 | 32 | $621.54 | |
| 84100 | 240 | 222 | $548.51 | |
| 82565 | 399 | 293 | $544.94 | |
| 86769 | 20 | 20 | $505.77 | |
| 82465 | 171 | 169 | $502.91 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 19 | 15 | $500.87 |
| 80177 | 43 | 41 | $404.25 | |
| 87075 | 88 | 88 | $385.37 | |
| 84550 | 183 | 180 | $382.12 | |
| 82274 | 34 | 34 | $347.94 | |
| 87081 | 170 | 169 | $345.04 | |
| 86160 | 21 | 21 | $336.34 | |
| 86141 | 38 | 38 | $330.98 | |
| 86762 | 67 | 67 | $327.42 | |
| 80076 | 96 | 96 | $309.55 | |
| 84520 | 257 | 185 | $291.49 | |
| 84703 | 59 | 59 | $278.21 | |
| 86431 | 85 | 85 | $254.37 | |
| 83516 | 30 | 24 | $250.11 | |
| 87427 | 41 | 41 | $243.88 | |
| 82670 | 14 | 14 | $241.64 | |
| 86708 | 45 | 45 | $227.21 | |
| 85660 | 58 | 58 | $207.77 | |
| 87045 | 43 | 43 | $198.54 | |
| 85060 | 13 | 13 | $182.91 | |
| 87338 | 16 | 16 | $170.43 | |
| 87209 | 14 | 14 | $146.34 | |
| 82330 | 20 | 20 | $134.09 | |
| 86704 | 28 | 28 | $133.56 | |
| 86709 | 35 | 35 | $124.69 | |
| 83020 | 12 | 12 | $123.60 | |
| 84166 | 12 | 12 | $123.60 | |
| 84207 | 24 | 24 | $113.09 | |
| 86787 | 14 | 14 | $107.46 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 12 | 12 | $96.86 |
| 80178 | 27 | 25 | $96.41 | |
| 82270 | 57 | 57 | $91.38 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 14 | 14 | $91.30 |
| 86340 | 24 | 24 | $86.82 | |
| 86901 | 39 | 39 | $74.88 | |
| 86900 | 38 | 38 | $72.92 | |
| 87177 | 27 | 26 | $26.86 | |
| 84156 | 13 | 13 | $21.98 | |
| 87902 | 16 | 16 | $16.00 | |
| 82947 | 12 | 12 | $7.31 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 28 | 27 | $0.52 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 188 | 187 | $0.00 |
| 80050 | General health panel | 85 | 85 | $0.00 |
| 84480 | 14 | 14 | $0.00 |